Distinct Deletions of Chromosome 9P Associated with Melanoma Versus Glioma, Lung Cancer, and Leukemia 1

Total Page:16

File Type:pdf, Size:1020Kb

Distinct Deletions of Chromosome 9P Associated with Melanoma Versus Glioma, Lung Cancer, and Leukemia 1 [CANCER RESEARCH54, 344--348, January 15,1994] Advances in Brief Distinct Deletions of Chromosome 9p Associated with Melanoma versus Glioma, Lung Cancer, and Leukemia 1 Aaron Coleman, Jane W. Fountain, Tsutomu Nobori, Olufunmilayo I. Olopade, Gavin Robertson, David E. Housman, and Tracy G. Lugo 2 Division of Biomedical Sciences, University of California, Riverside, California 92521 [A. C., G. R., T. G. L.]; Biology and Center for Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139 [J. W. F, D. E. H.]; Department of Medicine, University of California, San Diego, California 92093 [I. N.]; and Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, Illinois 60637 [0. L 0.] Abstract lines using probes that detect the IFN-a and D9S126 loci confirms the location of the telomeric 9p breakpoint in line AH between IFN-a and Deletions of DNA on chromosome 9p21-22 are frequently observed in MTAP and suggests that the analogous breakpoint in line FF resides cells derived from melanomas, gliomas, non-small cell lung cancers, and in a location centromeric to MTAP. acute lymphoblastic leukemia. The minimal deletion shared by the latter three cancers extends from the interferon-a locus towards the centromere; Materials and Methods its centromeric end is flanked by the gene encoding methylthioadenosine phosphorylase. We have determined that the telomeric end of the minimal Cell Lines and Culture Conditions. The origin of the human malignant homozygous deletion shared by two melanoma cell lines does not include melanoma cell lines FF (SK-Mel-133) and AH (SK-Mel-13) has been de- the methylthioadenosine phosphorylase locus. Thus, a distinct region of scribed (8). Ceils were routinely maintained in Dulbecco's modified Eagle's DNA is lost in melanoma. The physical size of this region remains to be medium plus 5% fetal calf serum without antibiotics. In some experiments, the defined precisely, but it may extend over several million base pairs. culture medium was supplemented with 10/xM AZ and 20 p~M MTA (both from Introduction Sigma Chemical Co.). Immunoblot Analyses. The presence of protein reactive with antiserum Frequent, nonrandom chromosomal breaks and deletions that are directed against human MTAP was determined by an immunoblot method as characteristic of particular cancers may indicate the sites of tumor described previously (9). Crude cell extracts (10-150/xg/lane) were separated suppressor genes. Such a pattern has been observed on chromosome by electrophoresis in a 12.5% polyacrylamide gel containing 0.1% sodium 9 in human malignant melanoma. Fountain et aI. (1) have detected dodecyl sulfate. Proteins were transferred by electroblotting to a nitrocellulose filter; nonspecific binding sites were blocked with 3% powdered milk in BBS loss of heterozygosity for DNA markers within chromosome band (0.2 Msodium borate-0.15 MNaC1, pH 8.5), and the filter was incubated for 16 9p21 in more than 80% of melanoma tumor and cell line DNAs tested. h at room temperature with anti-MTAP antiserum diluted 1:500 in BBS con- The critical region is defined by the overlap between homozygous taining 3% powdered milk. After the filter was washed with BBS, antibody was deletions in two melanoma cell lines, FF and AH, and is flanked by the detected by binding for 1 h to 125I-labeled protein A (1 mCi/ml; ICN Radio- IFN-ot3 locus on the telomeric end and the D9S3 marker on the chemicals, Irvine, CA), and the filter was exposed to Kodak XAR-5 film at centromeric end (Fig. 1). Rearrangements on chromosome 9 are also -70~ This procedure detects the Mr 32,000 homotrimeric subunit of the characteristic of other cancers, including gliomas (2), acute lympho- MTAP protein. blastic leukemia (3), and certain forms of lung cancer (4). The region Chromosome Studies. Metaphase chromosome spreads were prepared and of minimal overlap between deletions in a series of these malignancies subjected to Giemsa-trypsin banding according to procedures described pre- has been defined by Olopade et al. (5-7) and by James et al. (2). The viously (10). Photomicroscopy was performed on a Nikon Optiphot micro- scope equipped with a 100X planapochromatic objective. Cytogenetic abnor- critical region here extends from the IFN-ot locus towards the centro- malities are described according to the International System for Cytogenetic mere with its centromeric end flanked by the gene encoding MTAP. Nomenclature (11). In situ hybridization was carried out according to methods The homozygous deletion in the melanoma cell line AH extends into described in Ref. 12 using the chromosome 9-specific probe pBL-9 (kindly the centromeric portion of the interferon gene cluster, raising the provided by Dr. Daniel Pinkel, University of California at San Francisco, San possibility that a single locus in the vicinity of MTAP might be Francisco, CA). Following in situ hybridization, the biotin-labeled probe was implicated in all of these diverse cancers. However, we have deter- visualized by binding to streptavidin conjugated with fluorescein isothiocya- mined that the telomeric end of the deletion found in the melanoma nate (Vector Laboratories). The chromosomes were counterstained with prop- cell line FF does not include the MTAP locus. Thus, the region of idium iodide (Sigma) and observed under ultraviolet illumination through a overlap between the two melanoma deletions lies centromeric to Nikon B-2A filter (450-490 nm). MTAP and is distinct from that involved in glioma, lung cancer, and PFGE and DNA Hybridizations. PFGE and Southern blotting were car- ried out as described (13). High molecular weight DNA (5/xg) was prepared acute lymphoblastic leukemia. We have examined the chromosomes in low melting temperature agarose plugs, digested with an excess (>30 units) of these two melanoma cell lines and confirmed that a microscopically of NotI or MluI restriction enzyme, and loaded into a contour-clamp homoge- visible loss of chromosome 9p material has occurred in both of them. neous field electrophoresis gel consisting of 1.0% agarose. The gel was elec- Pulsed-field gel analysis of DNA restriction fragments from these cell trophoresed in TBE buffer (44.5 mM Tris-borate, 1 mM EDTA) at 10~ using a Pulsaphor unit (LKB) for 5 days at 90 V with a constant pulse time of 400 Received 10/7/93; accepted 11/24/93. s. Afterward, the gel was exposed briefly to UV radiation (330 nm transmitted The costs of publication of this article were defrayed in part by the payment of page and 254 nm reflected for 2.5 min each), denatured in 0.5 ra NaOH and 1.5 M charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. NaC1, and neutralized in 1 M Tris-HC1 and 1.5 M NaCI, pH 7.5. Transfer to a 1 This work was supported in part by Grants CA56910 (T. G. L.), HG00297 (D. E. H.), Zetabind membrane (AMF Cuno) was performed overnight in 10X SSC (1X = CA17575 (D. E. H.), and CA08985 (J. W. E) from the Cancer Research Coordinating 150 mM NaCI-15 mM sodium citrate). Prehybridizations and hybridizations Committee of the University of California and from the NIH. were carried out in a solution consisting of 50% formamide, 1 si NaCI, 25 mM 2 To whom requests for reprints should be addressed. 3 The abbreviations used are: IFN-ot, a-interferon; MTA, methylthioadenosine;MTAP, Tris (pH 7.5), IX Denhardt's solution, 6.7% dextran sulfate, 0.1% sodium methylthioadenosinephosphorylase; PFGE, pulsed-field gel electrophoresis;BBS, borate- dodecyl sulfate, and 500/xg/ml sheared DNA from salmon testes. Probes were buffered saline; SSC, standard saline citrate; AZ, azaserine. labeled by random primer extension, purified through a Sephadex G50-150 344 Downloaded from cancerres.aacrjournals.org on October 2, 2021. © 1994 American Association for Cancer Research. CHROMOSOME 9p DELETIONS IN MELANOMA hybridization (1). Since the D9S126 locus, centromeric to MTAP, is also homozygously deleted in cell line AH, we predicted that the MTAP gene would be lost as well. If so, this deletion would overlap the region identified in lung cancer, glioma, and acute lymphoblastic leukemia (Refs. 6 and 7; see Fig. 1). However, the telomeric extent of the homozygous deletion in cell line FF, which includes the D9S126 and D9S3 loci, has yet to be determined. No DNA probes corresponding to the MTAP gene were available for hybridization studies. We therefore examined the two melanoma Fig. 1. Overlap of homozygous9p deletions in human melanoma cell lines. Genotypes cell lines for evidence of the MTAP gene product. A preliminary of lymphoblastoid(B) and melanoma (Mel) cell lines from patients FF and AH are shown experiment tested the ability of the cells to survive in culture medium as describedpreviously (1). Gene loci are depicted in order from 9pter to centromeric9p; allele symbols are the same as those in Ref. 1 except for MTAP. Both melanomacell lines containing MTA and AZ. AZ is an inhibitor of de novo purine bio- have suffered loss of heterozygosity in these regions: AH at D9S33, IFNB1, IFNA, and synthesis. The MTAP enzyme permits a cell to use MTA as a source D9S3, and FF at D9S33 and IFNB1. Dashes, homozygous deletions; *, presence of of purine nucleotides for DNA synthesis via nucleotide salvage path- rearranged DNA fragments. The deleted or rearranged region shared by FF and AH melanoma cells is boxed. The shaded areas show the regions of overlap between homo- ways, and thus it confers the ability to survive under these selective zygous deletions in these melanoma cells and a separate region defined by overlapping conditions (15). The two cell lines exhibited markedly different be- deletions in glioma, lung cancer, and leukemiacells as describedby Olopade et aL (5-7).
Recommended publications
  • Assignment of the AK1:Np:ABO Linkage Group to Human Chromosome 9 (Somatic Cell Hybrids/Enzyme Markers/Gene Localization) A
    Proc. Nat. Acad. Sci. USA Vol. 73, No. 3, pp. 895-899, March 1976 Genetics Assignment of the AK1:Np:ABO linkage group to human chromosome 9 (somatic cell hybrids/enzyme markers/gene localization) A. WESTERVELD*§, A. P. M. JONGSMA*, P. MEERA KHANt, H. VAN SOMERENt, AND D. BOOTSMA* * Department of Cell Biology and Genetics, Erasmus University, Rotterdam, The Netherlands; t Department of Human Genetics, State University, Leiden, The Netherlands; and * Medical Biological Laboratory TNO, P.O. Box 45, Rijswijk 2100, The Netherlands Communicated by Victor A. McKusick, January 8,1976 ABSTRACT In man-Chinese hamster somatic cell hy- cytes were obtained from peripheral blood of male and fe- brids the segregation patterns of the loci for 25 human en- male donors. The details on production, isolation, and propa- zyme markers and human chromosomes were studied. The results provide evidence for the localization of the gene for gation of these hybrids have been published elsewhere (11). adenylate kinase-1 (AKI) on chromosome 9. Since the loci for In the hybrid and parental cell populations the following the ABO blood group (ABO), nail-patella syndrome (Np), and enzymes were analyzed by means of Cellogel electrophore- AK1 are known to be linked in man, the ABO.Np:AKj link- sis: glucose-6-phosphate dehydrogenase (G6PD); phospho- age group may be assigned to chromosome 9. glycerate kinase (PGK); a-galactosidase-A (a-Gal A); lactate dehydrogenases (LDH-A, LDH-B); 6-phosphogluconate de- In man several electrophoretically separable isoenzymes for hydrogenase (6PGD); phosphoglucomutases (PGMI, PGMs); adenylate kinase (AK; EC 2.7.4.3) have been described (1).
    [Show full text]
  • Methylthioadenosine Phosphorylase (MTAP) Is Frequent in High-Grade Gliomas; Nevertheless, It Is Not Associated with Higher Tumor Aggressiveness
    cells Article 0 Loss of 5 -Methylthioadenosine Phosphorylase (MTAP) is Frequent in High-Grade Gliomas; Nevertheless, it is Not Associated with Higher Tumor Aggressiveness Weder Pereira de Menezes 1, Viviane Aline Oliveira Silva 1 , Izabela Natália Faria Gomes 1 , Marcela Nunes Rosa 1 , Maria Luisa Corcoll Spina 1 , Adriana Cruvinel Carloni 1, Ana Laura Vieira Alves 1 , Matias Melendez 1, Gisele Caravina Almeida 2, Luciane Sussuchi da Silva 1 , Carlos Clara 3, Isabela Werneck da Cunha 4, Glaucia Noeli Maroso Hajj 4 , Chris Jones 5, Lucas Tadeu Bidinotto 1,6,7 and Rui Manuel Reis 1,8,9,* 1 Molecular Oncology Research Center, Barretos Cancer Hospital, Barretos, São Paulo 14.784-400, Brazil; [email protected] (W.P.d.M.); [email protected] (V.A.O.S.); [email protected] (I.N.F.G.); [email protected] (M.N.R.); [email protected] (M.L.C.S.); [email protected] (A.C.C.); [email protected] (A.L.V.A.); [email protected] (M.M.); [email protected] (L.S.d.S.); [email protected] (L.T.B.) 2 Department of Pathology, Barretos Cancer Hospital, Barretos, São Paulo 14.784-400, Brazil; [email protected] 3 Department of Neurosurgery, Barretos Cancer Hospital, Barretos, São Paulo 14.784-400, Brazil; [email protected] 4 A.C Camargo Cancer Center, São Paulo, São Paulo 015.080-10, Brazil; [email protected] (I.W.d.C.); [email protected] (G.N.M.H.) 5 Institute of Cancer Research, London SW7 3RP, UK; [email protected] 6 Barretos School of Health Sciences, Dr.
    [Show full text]
  • Chromosomal Assignment of the Genes for Human Aldehyde Dehydrogenase-1 and Aldehyde Dehydrogenase-2 LILY C
    Am J Hum Genet 38:641-648, 1986 Chromosomal Assignment of the Genes for Human Aldehyde Dehydrogenase-1 and Aldehyde Dehydrogenase-2 LILY C. Hsu,', AKIRA YOSHIDA,' AND T. MOHANDAS2 SUMMARY Chromosomal assignment of the genes for two major human aldehyde dehydrogenase isozymes, that is, cytosolic aldehyde dehydrogenase-1 (ALDH1) and mitochondrial aldehyde dehydrogenase-2 (ALDH2) were determined. Genomic DNA, isolated from a panel of mouse- human and Chinese hamster-human hybrid cell lines, was digested by restriction endonucleases and subjected to Southern blot hybridiza- tion using cDNA probes for ALDH1 and for ALDH2. Based on the distribution pattern of ALDH1 and ALDH2 in cell hybrids, ALDHI was assigned to the long arm of human chromosome 9 and ALDH2 to chromosome 12. INTRODUCTION Two major and at least two minor aldehyde dehydrogenase isozymes exist in human and other mammalian livers. One of the major isozymes, designated as ALDH 1, or E1, is of cytosolic origin, and another major isozyme, designated as ALDH2 or E2, is of mitochondrial origin. The two isozymes are different from each other with respect to their kinetic properties, sensitivity to disulfiram inactivation, and protein structure [1-5]. Remarkable racial differences be- tween Caucasians and Orientals have been found in these isozymes. Approxi- mately 50% of Orientals have a variant form of ALDH2 associated with dimin- ished activity, while virtually all Caucasians have the wild-type active ALDH2 Received July 10, 1985; revised September 23, 1985. This work was supported by grant AA05763 from the National Institutes of Health. ' Department of Biochemical Genetics, Beckman Research Institute of the City of Hope, Duarte, CA 91010.
    [Show full text]
  • Extra Euchromatic Band in the Qh Region of Chromosome 9
    J Med Genet: first published as 10.1136/jmg.22.2.156 on 1 April 1985. Downloaded from 156 Short reports two centromeres indicated by two distinct C bands but only I HANCKE AND K MILLER one primary constriction at the proximal C band. The two Department of Human Genetics, C bands were separated by chromosomal material staining Medizinische Hochschule Hannover, pale in G banding and intensely dark in R banding (fig 1). Hannover, Both NORs could be observed in satellite associations (fig Federal Republic of Germany. 2). The chromosome was therefore defined as pseudo- dicentric chromosome 21 (pseudic 21). The same chromo- References some was found in the proband's father and paternal Balicek P, Zizka, J. Intercalar satellites of human acrocentric grandmother. chromosomes as a cytological manifestation of polymorphisms Acrocentric chromosomes with a short arm morphology in GC-rich material? Hum Genet 1980;54:343-7. similar to that presented here have been reported by 2 Ing PS, Smith SD. Cytogenetic studies of a patient with Balicek and Zizka.' These authors paid no attention to the mosaicism of isochromosome 13q and a dicentric (Y;13) activity of the centromeres. The suppression of additional translocation showing differential centromeric activity. Clin centromeres is indicated by the presence of only one Genet 1983;24:194-9. primary constriction as shown by Ing and Smith2 in a 3 Passarge E. Analysis of chromosomes in mitosis and evaluation dicentric (Y;13) transtocation. Variants of acrocentric of cytogenetic data. 5. Variability of the karyotype. In: Schwarzacher HG, Wolf U, eds. Methods in human cytogene- chromosomes are often observed in patients with congen- tics.
    [Show full text]
  • Linear Increase of Structural and Numerical Chromosome 9 Abnormalities in Human Sperm Regarding Age
    European Journal of Human Genetics (2003) 11, 754–759 & 2003 Nature Publishing Group All rights reserved 1018-4813/03 $25.00 www.nature.com/ejhg ARTICLE Linear increase of structural and numerical chromosome 9 abnormalities in human sperm regarding age Merce` Bosch1, Osvaldo Rajmil2, Josep Egozcue3 and Cristina Templado*,1 1Departament de Biologia Cel.lular, Fisiologia i Immunologia, Facultat de Medicina, Universitat Auto`noma de Barcelona, Bellaterra 08193, Spain; 2Servei d’Andrologia, Fundacio´ Puigvert, Barcelona 08025, Spain; 3Departament de Biologia Cel.lular, Fisiologia i Immunologia, Facultat de Cie`ncies, Universitat Auto`noma de Barcelona, Bellaterra 08193, Spain A simultaneous four-colour fluorescence in situ hybridisation (FISH) assay was used in human sperm in order to search for a paternal age effect on: (1) the incidence of structural aberrations and aneuploidy of chromosome 9, and (2) the sex ratio in both normal spermatozoa and spermatozoa with a numerical or structural abnormality of chromosome 9. The sperm samples were collected from 18 healthy donors, aged 24–74 years (mean 48.8 years old). Specific probes for the subtelomeric 9q region (9qter), centromeric regions of chromosomes 6 and 9, and the satellite III region of the Y chromosome were used for FISH analysis. A total of 190 117 sperms were evaluated with a minimum of 10 000 sperm scored from each donor. A significant linear increase in the overall level of duplications and deletions for the centromeric and subtelomeric regions of chromosome 9 (Pr0.002), chromosome 9 disomy (Po0.0001) as well as diploidy (Po0.0001) was detected in relation to age. The percentage of increase for each 10-year period was 29% for chromosome 9 disomy, 18.8% for diploidy, and ranged from 14.6 to 28% for structural aberrations.
    [Show full text]
  • The Two Tort Dit U Nonton Un Mountin
    THETWO TORT DIT USU 20180010132A1NONTONUN MOUNTIN ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2018 / 0010132 A1 MAVRAKIS et al. ( 43 ) Pub . Date : Jan . 11 , 2018 ( 54 ) INHIBITION OF PRMT5 TO TREAT Publication Classification MTAP - DEFICIENCY- RELATED DISEASES (51 ) Int . CI. C12N 15 / 113 ( 2010 .01 ) (71 ) Applicant : NOVARTIS AG , Basel (CH ) A61K 45 / 06 ( 2006 . 01) ( 72 ) Inventors : Konstantinos John MAVRAKIS , A61K 31 / 7088 (2006 . 01 ) Boston , MA (US ) ; Earl Robert COZK 16 / 40 ( 2006 .01 ) MCDONALD , III , Wayland , MA (US ) ; A61K 39 /395 ( 2006 . 01 ) Frank Peter STEGMEIER , Acton , GOIN 33 /574 (2006 . 01 ) A61K 39 / 00 ( 2006 .01 ) MA (US ) (52 ) U . S . CI. CPC . .. C12N 15 / 1137 ( 2013 .01 ) ; A61K 39 /3955 ( 73 ) Assignee : Novartis AG , Basel (CH ) ( 2013 .01 ) ; A61K 45 / 06 ( 2013 .01 ) ; GOIN 33 /574 ( 2013. 01 ) ; C12Y 201/ 01 (2013 .01 ) ; ( 21 ) Appl. No. : 15 /510 , 542 A61K 31 /7088 (2013 .01 ) ; CO7K 16 / 40 ( 2013 .01 ) ; A61K 2039 /505 (2013 . 01 ) ; C12N ( 22 ) PCT Filed : Sep . 9 , 2015 2310 / 14 (2013 . 01 ) ; C12N 2320 / 31 ( 2013 .01 ) ; ( 86 ) PCT No .: PCT/ IB2015 /056902 CO7K 2317/ 76 ( 2013 .01 ) $ 371 (c ) ( 1 ) , (57 ) ABSTRACT ( 2 ) Date : Mar. 10 , 2017 The invention provides novel personalized therapies , kits , transmittable forms of information and methods for use in treating patients having cancer , wherein the cancer is Related U . S . Application Data MTAP - deficient and / or MTA -accumulating and thus ame (60 ) Provisional application No . 62/ 131 ,437 , filed on Mar . nable to therapeutic treatment with a PRMT5 inhibitor. Kits , 11 , 2015 , provisional application No .
    [Show full text]
  • Duplication 9P and Their Implication to Phenotype
    Guilherme et al. BMC Medical Genetics (2014) 15:142 DOI 10.1186/s12881-014-0142-1 RESEARCH ARTICLE Open Access Duplication 9p and their implication to phenotype Roberta Santos Guilherme1, Vera Ayres Meloni1, Ana Beatriz Alvarez Perez1, Ana Luiza Pilla1, Marco Antonio Paula de Ramos1, Anelisa Gollo Dantas1, Sylvia Satomi Takeno1, Leslie Domenici Kulikowski2 and Maria Isabel Melaragno1* Abstract Background: Trisomy 9p is one of the most common partial trisomies found in newborns. We report the clinical features and cytogenomic findings in five patients with different chromosome rearrangements resulting in complete 9p duplication, three of them involving 9p centromere alterations. Methods: The rearrangements in the patients were characterized by G-banding, SNP-array and fluorescent in situ hybridization (FISH) with different probes. Results: Two patients presented de novo dicentric chromosomes: der(9;15)t(9;15)(p11.2;p13) and der(9;21)t(9;21) (p13.1;p13.1). One patient presented two concomitant rearranged chromosomes: a der(12)t(9;12)(q21.13;p13.33) and an psu i(9)(p10) which showed FISH centromeric signal smaller than in the normal chromosome 9. Besides the duplication 9p24.3p13.1, array revealed a 7.3 Mb deletion in 9q13q21.13 in this patient. The break in the psu i(9) (p10) probably occurred in the centromere resulting in a smaller centromere and with part of the 9q translocated to the distal 12p with the deletion 9q occurring during this rearrangement. Two patients, brother and sister, present 9p duplication concomitant to 18p deletion due to an inherited der(18)t(9;18)(p11.2;p11.31)mat.
    [Show full text]
  • Specific Targeting of MTAP-Deleted Tumors with a Combination of 2 ′-Fluoroadenine and 5′-Methylthioadenosine
    Published OnlineFirst May 29, 2018; DOI: 10.1158/0008-5472.CAN-18-0814 Cancer Translational Science Research Specific Targeting of MTAP-Deleted Tumors with a Combination of 20-Fluoroadenine and 50-Methylthioadenosine Baiqing Tang, Hyung-Ok Lee, Serim S. An, Kathy Q. Cai, and Warren D. Kruger Abstract Homozygous deletion of the methylthioadenosine phos- dependent manner, shifting the IC50 concentration by one to phorylase (MTAP) gene is a frequent event in a wide variety of three orders of magnitude. However, in mice, MTA protected human cancers and is a possible molecular target for therapy. against toxicity from 2FA but failed to protect against 6TG. One potential therapeutic strategy to target MTAP-deleted Addition of 100 mg/kg MTA to 20 mg/kg 2FA entirely reversed tumors involves combining toxic purine analogues such as the toxicity of 2FA in a variety of tissues and the treatment was 60-thioguanine (6TG) or 20-fluoroadenine (2FA) with the well tolerated by mice. The 2FAþMTA combination inhibited À MTAP substrate 50-deoxy-50-methylthioadenosine (MTA). The tumor growth of four different MTAP human tumor cell lines þ rationale is that excess MTA will protect normal MTAP cells in mouse xenograft models. Our results suggest that 2FAþMTA from purine analogue toxicity because MTAP catalyzes the may be a promising combination for treating MTAP-deleted conversion of MTA to adenine, which then inhibits the con- tumors. version of purine base analogues into nucleotides. However, À in MTAP tumor cells, no protection takes place because Significance: Loss of MTAP occurs in about 15% of all adenine is not formed.
    [Show full text]
  • Chromosome 9 Deletions and Recurrence of Superficial
    Oncogene (2000) 19, 6317 ± 6323 ã 2000 Nature Publishing Group All rights reserved 0950 ± 9232/00 $15.00 www.nature.com/onc Chromosome 9 deletions and recurrence of super®cial bladder cancer: identi®cation of four regions of prognostic interest Maryse Simoneau1,He leÁ ne LaRue1, Tahar O Aboulkassim1, FrancËois Meyer1, Lynne Moore1 and Yves Fradet*,1 1Centre de recherche en canceÂrologie de l'Universite Laval, Centre Hospitalier Universitaire de QueÂbec, Pavillon L'HoÃtel-Dieu de QueÂbec, QueÂbec, Canada In a previous study, loss of heterozygosity (LOH) of 28 various grades and stages, however, in low stage chromosome 9 microsatellite markers was assessed on tumors, they are often the only genetic anomaly 139 Ta/T1 bladder tumors. LOH at one or more loci identi®ed. In a previous study of chromosome 9 was detected in 67 tumors, 62 presenting subchromoso- LOH on a series of 139 primary Ta, T1 bladder mal deletions. One hundred and thirty-three of these tumors obtained at initial diagnosis (Simoneau et al., patients have now been followed for up to 8 years. The 1999) we found deletion of at least one chromosome 9 purpose of the present study was to evaluate the potential marker in 48% of tumors. Chromosome 9 monosomy biological signi®cance of chromosome 9 deletions in was a rare event and deletions on 9q were twice as super®cial bladder tumors at initial diagnosis. High frequent as deletions on 9p. Moreover, only 4% of grade was associated with LOH (P=0.004). Large cases had deletions on 9p only. This suggests that tumors carried more frequently 9p deletions (P=0.022).
    [Show full text]
  • CDKN2A and MTAP Deletions in Peritoneal Mesotheliomas Are Correlated with Loss of P16 Protein Expression and Poor Survival
    Modern Pathology (2010) 23, 531–538 & 2010 USCAP, Inc. All rights reserved 0893-3952/10 $32.00 531 CDKN2A and MTAP deletions in peritoneal mesotheliomas are correlated with loss of p16 protein expression and poor survival Alyssa M Krasinskas1, David L Bartlett2, Kathleen Cieply1 and Sanja Dacic1 1Department of Pathology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA and 2Division of Surgical Oncology, Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, PA, USA Homozygous deletion of CDKN2A (p16) is one of the most common genetic alterations in pleural mesotheliomas, occurring in up to 74% of cases. MTAP resides in the same gene cluster of the 9p21 region and is co-deleted in the majority of CDKN2A deleted cases. This study examines the genetic alterations in peritoneal mesotheliomas, which may have a different pathogenesis than their pleural counterparts. Twenty-six cases of peritoneal mesotheliomas in a triplicate tissue microarray were studied. Dual-color fluorescence in situ hybridization was performed with CDKN2A and MTAP locus-specific probes. Nine of 26 (35%) peritoneal mesotheliomas had homozygous deletion of CDKN2A; MTAP was co-deleted in every case. All cases with CDKN2A deletions had loss of p16 protein expression; five cases had loss of p16 protein without evidence of CDKN2A deletions. All patients with CDKN2A deletions were men (P, NS) and were significantly older (mean, 63 years) than the patients with no deletions (mean, 52 years) (P ¼ 0.033, t-test). An association with asbestos exposure could not be proved in this study. Similar to pleural mesotheliomas, patients with CDKN2A deletions and loss of p16 protein expression had worse overall and disease-specific survival (P ¼ 0.010 and 0.006, respectively; Kaplan–Meier log rank).
    [Show full text]
  • Methylthioadenosine Phosphorylase at 1.7 Å Resolution Provides Insights Into Substrate Binding and Catalysis Todd C Appleby1, Mark D Erion2 and Steven E Ealick3*
    View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Elsevier - Publisher Connector Research Article 629 The structure of human 5′-deoxy-5′-methylthioadenosine phosphorylase at 1.7 Å resolution provides insights into substrate binding and catalysis Todd C Appleby1, Mark D Erion2 and Steven E Ealick3* Background: 5′-Deoxy-5′-methylthioadenosine phosphorylase (MTAP) Addresses: 1Section of Biochemistry, Molecular and catalyzes the reversible phosphorolysis of 5′-deoxy-5′-methylthioadenosine Cell Biology, Cornell University, Ithaca, NY 14853, USA and 2Metabasis Therapeutics, Inc., 9390 Town (MTA) to adenine and 5-methylthio-D-ribose-1-phosphate. MTA is a by-product Center Drive, San Diego, California 92121, USA of polyamine biosynthesis, which is essential for cell growth and proliferation. and 3Department of Chemistry and Chemical This salvage reaction is the principle source of free adenine in human cells. Biology, Cornell University, Ithaca, NY 14853, USA. Because of its importance in coupling the purine salvage pathway to polyamine *Corresponding author. biosynthesis MTAP is a potential chemotherapeutic target. Email: [email protected] Results: We have determined the crystal structure of MTAP at 1.7 Å resolution Key words: methylthioadenosine phosphorylase, using multiwavelength anomalous diffraction phasing techniques. MTAP is a multiwavelength anomalous diffraction, purine trimer comprised of three identical subunits. Each subunit consists of a single nucleoside phosphorylase, salvage pathway α β β / domain containing a central eight-stranded mixed sheet, a smaller five- Received: 18 January 1999 stranded mixed β sheet and six α helices. The native structure revealed the Revisions requested: 17 February 1999 presence of an adenine molecule in the purine-binding site.
    [Show full text]
  • WNT16 Is a New Marker of Senescence
    Table S1. A. Complete list of 177 genes overexpressed in replicative senescence Value Gene Description UniGene RefSeq 2.440 WNT16 wingless-type MMTV integration site family, member 16 (WNT16), transcript variant 2, mRNA. Hs.272375 NM_016087 2.355 MMP10 matrix metallopeptidase 10 (stromelysin 2) (MMP10), mRNA. Hs.2258 NM_002425 2.344 MMP3 matrix metallopeptidase 3 (stromelysin 1, progelatinase) (MMP3), mRNA. Hs.375129 NM_002422 2.300 HIST1H2AC Histone cluster 1, H2ac Hs.484950 2.134 CLDN1 claudin 1 (CLDN1), mRNA. Hs.439060 NM_021101 2.119 TSPAN13 tetraspanin 13 (TSPAN13), mRNA. Hs.364544 NM_014399 2.112 HIST2H2BE histone cluster 2, H2be (HIST2H2BE), mRNA. Hs.2178 NM_003528 2.070 HIST2H2BE histone cluster 2, H2be (HIST2H2BE), mRNA. Hs.2178 NM_003528 2.026 DCBLD2 discoidin, CUB and LCCL domain containing 2 (DCBLD2), mRNA. Hs.203691 NM_080927 2.007 SERPINB2 serpin peptidase inhibitor, clade B (ovalbumin), member 2 (SERPINB2), mRNA. Hs.594481 NM_002575 2.004 HIST2H2BE histone cluster 2, H2be (HIST2H2BE), mRNA. Hs.2178 NM_003528 1.989 OBFC2A Oligonucleotide/oligosaccharide-binding fold containing 2A Hs.591610 1.962 HIST2H2BE histone cluster 2, H2be (HIST2H2BE), mRNA. Hs.2178 NM_003528 1.947 PLCB4 phospholipase C, beta 4 (PLCB4), transcript variant 2, mRNA. Hs.472101 NM_182797 1.934 PLCB4 phospholipase C, beta 4 (PLCB4), transcript variant 1, mRNA. Hs.472101 NM_000933 1.933 KRTAP1-5 keratin associated protein 1-5 (KRTAP1-5), mRNA. Hs.534499 NM_031957 1.894 HIST2H2BE histone cluster 2, H2be (HIST2H2BE), mRNA. Hs.2178 NM_003528 1.884 CYTL1 cytokine-like 1 (CYTL1), mRNA. Hs.13872 NM_018659 tumor necrosis factor receptor superfamily, member 10d, decoy with truncated death domain (TNFRSF10D), 1.848 TNFRSF10D Hs.213467 NM_003840 mRNA.
    [Show full text]